On October 29th, Gelonhui reported that Tus-Pharmaceutical Group (000590.SZ) announced its third quarter report for 2024, with the company achieving revenue of 0.216 billion yuan for the first three quarters, a year-on-year decrease of 21.26%; net income attributable to shareholders of the listed company was -28.4545 million yuan; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was -31.8838 million yuan; and basic earnings per share was -0.1188 yuan.
启迪药业(000590.SZ)：前三季度净亏损2845.45万元
tus-pharmaceutical group (000590.SZ): a net loss of 28.4545 million yuan in the first three quarters.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated